Dr. Eoin Brennan is an Assistant Professor in Clinical Pharmacology at UCD and Principal Investigator at the Conway Institute. He earned his honours degree in Genetics from UCC and his PhD from Queen’s University Belfast, where he studied the genetic and epigenetic mechanisms of diabetic kidney disease. Dr Brennan leads translational projects on vascular disease and nanomedicine, including studies of RNA molecules in atherosclerosis, aiming to translate genetic insight into patient-relevant therapies.
Dual-Agonist Anti-Inflammatory Compounds
New approach to promote resolution of inflammation. Developed hybrid compounds that are dual agonists of FPR2 and GPR32.
Lead: Dr. Eoin Brennan, Prof. Catherine Godson, Prof. Patrick Guiry
